AAAAI 2021 Results of the SYNAPSE study for CRSwNP

Watch Here

Medscape ReCAP of new science at the American Rhinologic Society 2020 virtual meeting

Watch Here

Targeting Inflammation: Biologic Immunomodulators For Moderate-to-Severe Chronic Rhinosinusitis with Nasal Polyps – An Animated Whiteboard View

This enduring activity is focused on the care of patients with chronic rhinosinusitis with nasal polyps.

Stella E. Lee, MD

Learn More

Chronic Rhinosinusitis with Nasal Polyps — Dupilumab, a New Therapy


Chronic Rhinosinusitis With Nasal Polyposis: Early Diagnosis

Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a common condition that significantly affects quality of life and results in more than a million surgeries a year worldwide.

Symptoms of CRSwNP often mimic allergic rhinitis or bacterial rhinosinusitis, and patients frequently receive inappropriate prescriptions for allergy medications and even multiple courses of antibiotics. But appropriate therapeutic intervention can help to relieve CRSwNP symptoms, prevent unnecessary pain and suffering, reduce disease progression, and potentially prevent the need for nasal polypectomy.

Dr Stella Lee from the University of Pittsburgh discusses the importance of early and accurate diagnosis of CRSwNP, which is now viewed as a long-term, systemic inflammatory disorder, as well as strategies to assess symptom and disease severity.

Watch Here

References

nose.png
 
 

European Position Paper on Rhinosinusitis and Nasal Polyps 2020

Visit Reference

Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size

Visit Reference

EUFOREA consensus on biologics for CRSwNP with or without asthma

Visit Reference

International Consensus Statement on Allergy and Rhinology: Rhinosinusitis

Visit Reference

Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

Visit Reference

abScent.png
Visit Reference